Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709332 | 0.91 | MEN1 (0.61) | MEN1KMT2AECE1FAAHCNR1 | |
| SCHEMBL29509517 | 0.84 | ECE1 (0.57) | MEN1KMT2AECE1FAAHCNR1 | |
| SCHEMBL30744226 | 0.83 | ECE1 (0.50) | MEN1KMT2AECE1FAAHCNR1 | |
| SCHEMBL23471380 | 0.82 | MEN1 (0.48) | MEN1KMT2AFAAHPLA2G2ARECQL | |
| SCHEMBL15136719 | 0.81 | ECE1 (0.52) | MEN1KMT2AECE1FAAHCNR1 | |
| SCHEMBL14197498 | 0.80 | MEN1 (0.58) | MEN1KMT2ACNR1RECQLPSMB5 | |
| SCHEMBL27147999 | 0.80 | HDAC3 (0.43) | KMT2AECE1FAAHCNR1CNR2 | |
| SCHEMBL20556361 | 0.80 | FAAH (0.72) | MEN1KMT2AFAAHCNR1CNR2 | |
| SCHEMBL13631859 | 0.79 | ECE1 (0.50) | KMT2AECE1FAAHCNR1CNR2 | |
| SCHEMBL22819452 | 0.79 | ECE1 (0.50) | MEN1KMT2AECE1FAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MEN1 394/4885KMT2A 4608/4885ECE1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.